Lite Strategy, Inc. Common Stock
Market Cap
28M
Short interest (May 15)
0.2%
Net Short (Jun 03 ): -0.1%
Borrow Fee
18.55%
↑ 2.2%
Available Shares
6M
↑ 1.9%
Price Chart
Company Overview
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.
Company Info
Market Data
Short Interest
Recent Changes
Quick Actions
Investment Risk
This is not financial advice. All investments carry risk. Do your own research before making investment decisions.